Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has officially launched its innovative medical base in Zhuhai, Guangzhou, focusing on the development and manufacturing of neuro-interventional products, aiming to stand out in a highly competitive market through unique "micro-innovations" and a comprehensive product portfolio [1][5]. Group 1: Company Overview - The newly opened Tongqiao Medical Innovation Base integrates R&D, high-end manufacturing, and industrialization [1]. - The company has developed a unique "weaving" technology for its nickel-titanium alloy stents, which are used for treating brain aneurysms [1]. - Guichuang Tongqiao currently offers the most comprehensive range of neuro and peripheral vascular interventional medical devices among domestic companies, with 73 products in total, of which 51 have been approved for sale in China [5]. Group 2: Production and Capacity - The production line is currently operating at full capacity, with plans to increase production capacity by seven to eight times once the new base is fully operational [2]. - Most core components are self-manufactured, and the company is enhancing quality stability and product yield through automation [2]. - The company has experienced significant growth in overseas orders, indicating strong demand for its products [2]. Group 3: Market Trends and Opportunities - The neuro-interventional market in China is expected to grow to 37.1 billion yuan by 2030, with the number of related surgeries projected to reach 881,300 [3]. - The domestic market has seen a shift towards local products due to high prices of foreign alternatives, creating opportunities for local companies [3]. - Guichuang Tongqiao has benefited from multiple rounds of centralized procurement since 2022, which has facilitated rapid product adoption in hospitals [6][7]. Group 4: Innovation Strategy - The company focuses on "micro-innovations" to differentiate itself in a crowded market, with recent innovations including a unique stent design that minimizes damage to blood vessel walls [4]. - Guichuang Tongqiao has several products in the pipeline, including the first domestic dual-layer carotid stent and a self-expanding aneurysm embolization device [4]. Group 5: International Expansion - The company is actively pursuing international markets, with 22 products commercialized in 27 countries and over 31 products undergoing registration in 23 countries [7]. - Guichuang Tongqiao has established strategic partnerships with over 60 global companies and is preparing for further international expansion through potential acquisitions [8].
归创通桥：“金属丝”疏通生命桥